SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on novel cancer treatments, announced today the appointment of Dan Kirby (NYSE:KEX) as Chief ...
Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that ...
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...
Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics ... system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising ...
Iovance Biotherapeutics (IOVA) announced that Dan Kirby will join the Company’s executive leadership team in the newly created role of Chief ...
Iovance Biotherapeutics (NASDAQ ... The company seeks to develop therapies that enhance patients' cancer-fighting cells, specifically tumor-infiltrating lymphocytes (TILs). Iovance collects ...
I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team,” stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback